论文部分内容阅读
目的:探讨不同剂量牛肺表面活性物质(珂立苏)治疗早产儿呼吸窘迫综合征的临床疗效。方法:选取我院2012年9月至2014年9月收治的227例新生儿呼吸窘迫综合征(NRDS)早产儿作为研究对象,均给予牛肺表面活性物质治疗,将患儿随机分为标准剂量组(70 mg/kg)117例、高剂量组(100 mg/kg)110例,比较两组用药后1 h、6 h、12 h、24 h、48 h呼吸机参数、血气指标、通气时间和并发症发生率。结果:高剂量组用药6 h、12 h、24 h、48 h平均气道压(MAP)低于标准剂量组(P<0.05);高剂量组用药1 h、6 h、12 h、24 h、48 h后吸入氧浓度(Fi O2)低于标准剂量组(P<0.05)。高剂量组用药1 h、6 h、24 h、48 h动脉血二氧化碳分压(PCO2)均低于标准剂量组,动脉血氧分压(PO2)高于标准剂量组(P<0.05);高剂量组用药6 h、12 h、24 h后氧合指数(OI)均低于标准剂量组(P<0.05)。高剂量组新生儿肺表面活性物质(PS)用药次数、通气时间均少于标准剂量组(P<0.05)。高剂量组并发症发生率为8.18%,低于标准剂量组的18.80%(P<0.05)。结论:牛肺表面活性物质治疗NRDS时,首剂用药剂量应满足100 mg/kg,安全有效。
Objective: To investigate the clinical effects of different doses of bovine pulmonary surfactant (Ke Li Su) treatment of respiratory distress syndrome in preterm children. Methods: A total of 227 neonatal respiratory distress syndrome (NRDS) preterm infants admitted to our hospital from September 2012 to September 2014 were selected as study subjects. All patients were treated with bovine pulmonary surfactant, and the children were randomly divided into standard dose One hundred and seventy-one patients (70 mg / kg) and 110 patients in the high-dose group (100 mg / kg) were enrolled. The ventilatory parameters, blood gas indexes, And complication rate. Results: The mean airway pressure (MAP) at 6 h, 12 h, 24 h and 48 h in the high dose group was lower than that in the standard dose group (P <0.05). The high dose group took 1 h, 6 h, 12 h, 24 h After 48 h, FiO2 was lower than the standard dose (P <0.05). The arterial partial pressure of carbon dioxide (PCO2) at 1 h, 6 h, 24 h and 48 h in the high dose group was lower than the standard dose group, and the PO2 was higher than the standard dose group (P <0.05). Oxygenation index (OI) in the dosage group at 6 h, 12 h and 24 h were lower than the standard dosage group (P <0.05). The number of pulmonary surfactant (PS) administration and the ventilation time of neonates in high dose group were less than those of standard dose group (P <0.05). The incidence of complications in the high-dose group was 8.18%, lower than the 18.80% of the standard dose group (P <0.05). Conclusion: When the bovine pulmonary surfactant is used in the treatment of NRDS, the dosage of the first dose should meet 100 mg / kg, which is safe and effective.